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The Use of High Doses of Oxycodone
in an Acute Palliative Care Unit
Sebastiano Mercadante, MD1,2, Patrizia Ferrera, MD1,
Fabrizio David, MD1, and Alessandra Casuccio, BS3
Abstract
A retrospective study of patients who were prescribed controlled-release oxycodone (CRO) in a period of 3 years (2006-2008)
was performed. A total of 212 patients were prescribed at discharge CRO for background analgesia; 129, 43, and 40 patients were
prescribed doses of oxycodone of less than 120 mg/day (group L), 120 to 240 mg/day (group M), and more than 240 mg/day
(group L), respectively. No differences in gender, primary diagnosis, and pain mechanisms were found, but doses were significantly
lower in older patients (P < .0005). At discharge, adverse effects were mild and only a minority of patients were switched to other
opioids. This study demonstrated that CRO administered in larger doses was safe and effective, showing versatility and flexibility
similar to morphine.
Keywords
oxycodone, cancer pain, opioids, palliative care, supportive care, adverse effects
The analgesic ladder recommended by the WHO has been
shown to provide efficient pain relief for a large number of can-
cer patients. Opioid administration is the primary therapeutic
modality in the management of moderate-to-severe cancer
pain. Morphine is considered the preferred drug because of its
wide availability, varied formulations, and well-characterized
pharmacologic properties.1 Efficacious doses of morphine have
a wide range, due to individual differences. Sometime mor-
phine doses titrated individually to achieve adequate pain relief
can require extremely high doses. Oral morphine has been
shown to be a safe analgesic drug even in the high-dose range
(more than 300 mg/day).2-4
Oxycodone was originally formulated in combination with
nonopioids. Subsequently, oxycodone was shown to be as ver-
satile and flexible as oral morphine in the management of can-
cer pain.5 Controlled-release oxycodone (CRO) is widely
accepted as an alternative to morphine, resulting as safe and
effective as controlled-release morphine.6 The use of relatively
high doses of CRO (mean daily dose of about 230 mg) in ter-
minal cancer patients was safe, efficient, and unrelated to
shorter survival times.7
This article characterizes patients admitted to an acute pain
relief and palliative care unit who received even larger doses of
CRO for the management of cancer pain.
Patients and Methods
A retrospective study of a consecutive population of patients
who were prescribed CRO during admission at an acute
pain relief and palliative care unit in a period of 3 years
(2006-2008) was performed. For each patient included in the
study, demographic parameters, site of tumor, characteristics
of pain, hospital stay, and doses of CRO prescribed at discharge
were recorded.
Pain intensity was assessed by a numerical scale 0 to 10 and
symptoms associated with opioid therapy or commonly present
in patients with advanced cancer, such as nausea and vomiting,
drowsiness, confusion, constipation, dry-mouth, and so on,
using a scale from 0 to 3 (not at all, slight, a lot, awful), were
recorded. Symptoms were assessed by the patient. Discress
score (DS) was calculated from the sum of symptom intensity.
During hospitalization, decisions regarding the administration
of opioids and adjustment of dosage were based on assessment,
patient’s daily report, and rescue doses given during the pre-
ceding 24 hours. Patients are discharged home when pain doses
are presumably stabilized and pain control has been achieved.
The study sought to establish whether prescription of large
doses of CRO was safe and effective. For this purpose, patients
were divided in 3 groups: L (dose less of 120 mg/day),
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M (doses in the range of 120-240 mg 7 day), and L (doses
higher than 240 mg/day).
Statistical Analysis
Data were analyzed by the Epi Info software (version 6.0,
CDC, Atlanta, Georgia) and the SPSS Software 14.0 version
(SPSS, Inc, Chicago, Illinois). Frequency analysis was per-
formed with chi-square test. The one-way analysis of variance
(ANOVA) was performed to evaluate difference in parametric
variables. Moreover, to explore a relationship among doses of
CRO and patients’ characteristics, a series of logistic regression
analyses were conducted. Independent variables included age,
gender, and characteristics of pain. All P values were 2-sided
and P values less than .05 were considered to indicate statistical
significance.
Results
Of 1526 patients admitted in 3 years for pain and symptom con-
trol, 998 patients were discharged home with a strong opioid
prescription. Globally, 234 patients were prescribed CRO dur-
ing admission. Twenty-two patients were switched to the
opioids, and 34 patients were switched to CRO. We collected
212 patients who were prescribed at discharge CRO for back-
ground analgesia (patients who initiated CRO and continued
until discharge or who were switched to CRO). The mean age
was 62.4 (13.2) years and 118 patients were males. Primary
diagnoses were in a rank order: gastrointestinal (54), lung
(52), urogenital (46), breast (27), others (33). Overall, the mean
dose of oxycodone was 141 mg (+167, range 10-960 mg). In
all, 129, 43, and 40 patients were prescribed doses of oxyco-
done of less than 120 mg/day (group L), 120 to 240 mg/day
(group M), and more than 240 mg/day (group L), respectively.
The mean doses in the 3 groups were 48.4+ 25, 156.5+ 30.5,
and 435 + 196, respectively. No differences in gender, pri-
mary diagnosis, and pain mechanisms were found (P ¼ .067,
P ¼ .43, and P ¼ .783, respectively). Doses were significantly
lower in older patients (P < .0005). The mean admission time
was 4.8 (+3.2) days. At hospital discharge, mean pain inten-
sity was 2.9 (+1.9), adverse effects were mild in intensity
(DS ¼ 3.5+ 1.7) and were not related to CRO doses (P < 0.19).
Discussion
Effectiveness and safety of high doses of opioids have been
poorly reported in literature. In hospice and home care series
of patients receiving oral morphine, 9% to 12% of patients
required doses higher than 300 mg/day. Such relatively high
doses did not influence the survival, attesting the safety of high
doses of opioids in patients with advanced cancer who were
responsive.3,4 Similarly, doses in the range of 720 to 1100 mg
of oral morphine were tolerated in very advanced cancer
population.2
Oxycodone has been found to be as effective as morphine6
and is the preferred drug for switching from morphine in
United Kingdom.8 Although recent data suggested that
oxycodone is efficacious and well tolerated as a first-line
opioid in doses of 20 to 40 mg/day after 3 weeks,9 few reports
have assessed patients receiving high doses of oxycodone. In
an early experience, the mean highest doses of CRO were
160 mg after 12 weeks of treatment.10 In a more recent study,
the maximum mean dose was about 230 mg/day in patients
with very advanced cancer with a mean survival of 12 days.
High doses were unrelated to survival time.7 Finally, in a mixed
Italian population recruited in different settings, doses of CRO
achieved after an average treatment duration of 37 days were
221 mg/day.11
In our experience, such doses are not considered particularly
high, possibly due to the selection of patients admitted in our
unit, who are already receiving opioids at relevant doses, and
have a long-term survival. Most patients were receiving opioids
and were titrated or switched to oxycodone to obtain the best
balance between analgesia and adverse effects. According to
existing studies reporting on high doses of CRO, we divided
patients who were discharged home with a prescription of oxy-
codone in 3 groups, and considered high doses only those
superior to the mean maximum doses administered in previous
studies. According to department policy, patients are dis-
charged home only on stable doses capable to maintain an
acceptable pain relief (pain intensity of 4 on a numerical
scale 0-10 and 2-3 doses of opioids as needed for breakthrough
pain) and tolerable adverse effects. This study demonstrated
that CRO administered in very high doses compared to those
recorded in previous studies with the same purposes was safe
and effective, showing versatility and flexibility similar to mor-
phine, with doses titrated against intensity of pain.
As morphine, CRO showed a typical interindividual varia-
bility in doses. Although in an hospice experience age and gen-
der did not influence the CRO dose,7 in this study, older
patients received doses significantly lower in older patients.
The difference may be related to the different population exam-
ined. Of interest, most of the patients examined were still on
oncologic treatment and had a prolonged survival, differently
from patients with a very short survival typically observed in
hospice patients.7 Survival, although presumably longer, was
not addressed, and patients who died in the unit were not
accounted for the study. The lower doses of CRO found in
older population reflect similar observation reported with other
opioids12 and are likely to be related to well-known pharmaco-
kinetics of opioids in aged population.13,14 Pain mechanisms
did not influence CRO doses, remarking the potential efficacy
of oxycodone in the different types of pain, including neuro-
pathic pain.15 Given the retrospective nature of this study, adju-
vants were freely administered. However, the consumption of
adjuvants was not different from that reported with other
opioids. The role of CRO in patients with neuropatic pain
should be better addressed in appropriate study with specific
designs and is beyond the aim of the current study.
Adverse effects were rarely dose-limiting, and safety was
witnessed at time of discharge, which, as per protocol, required
the achievement of an acceptable balance between analgesia
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and adverse effects. Patients were dischargedwith an acceptable
DS, which has been used to globally monitor the intensity of
opioid-related symptoms.16 It is expected, however, that after
starting titration with CRO, 15% of patients may discontinue the
drug for adverse effects.9,10 In this study, only a minority of
patients were switched to other opioids during admission
(9.4%). The principal limits of this survey is the retrospective
analysis, which, however, has a little influence on the results
reported, according to which high doses of CRO, over
240 mg/day, are safe and effective.
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